W25
An anti-RBD (SARS-CoV-2 Spike) nanobody.
General information
W25 is a monomeric nanobody identified using an Escherichia coli surface display technique for its affinity for the SARS-CoV-2 Spike RBD. It is derived from a B-lymphocyte clone from an immunized alpaca (Nieto et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody
Spike protein ACE2 In vitro Antibody |
in vitro binding assay; HeLa cells; Vero E6 cells; SARS-CoV-2 isolates QLD02/2020—30/1/2020 ("D614") and QLDID935/2020—25/03/2020 ("G614") | 4.00 | The nanobady bound to SARS-CoV-2 Spike protein RBD with an estimated EC50 of 33 nM in vitro. Unmodified or fused with human dimeric or monomeric Fc, it neutralized SARS-CoV-2 (Spike variants D614 or G614). The IC50 values ranged from ca. 3.69 nM (G614; dimeric Fc fusion) to ca. 27.4 nM (D614; monomeric Fc fusion). |
Feb/08/2021 |
